Indonesia Adult Malignant Glioma Therapeutics Market Analysis

Indonesia Adult Malignant Glioma Therapeutics Market Executive Summary

The Indonesia Adult Glioma Therapeutics Market is valued at around $13 Mn in 2022 and is projected to reach $26 Mn by 2030, exhibiting a CAGR of 8.9% during the forecast period.

Adult Malignant Glioma is a form of brain tumour caused by glial cells, which support neurons and assist the function of the central nervous system. Based on the cells from which they originate and how they look under the microscope, they may be divided into several subtypes. Astrocytomas, oligodendrogliomas, and ependymomas are the three primary forms of gliomas. Glioblastoma Multiforme (GBM) is a type of astrocytoma, which is the most dangerous form. Treatment for gliomas has advanced recently using a variety of strategies, including targeted therapy, virotherapy, and the discovery of possible novel medications. Glioma treatment options such as virotherapy, which utilizes genetically engineered viruses to attack tumour cells, have shown promise. Gliomas can be treated with radiation treatment, chemotherapy, and surgery. Drugs used in targeted treatment, such as Vorasidenib, have shown promise in slowing the growth of gliomas.

Among the countries of Southeast Asia, Indonesia has a noticeably greater rate of primary brain tumours, including gliomas. There can be geographical differences in the frequency of gliomas in various regions of the country. In Indonesia, GBM is still the most frequent kind of glioma. The UHC program of the Indonesian government, together with the nation's expanding economic might and a rise in domestic investment and research projects, is greatly boosting the manufacture of generic drugs domestically and encouraging the development of diagnostic and therapeutic technologies.

Certain sectors, such as first-line chemotherapy, are dominated by multinational giants. Temozolomide from Roche and Bevacizumab, an anti-angiogenic treatment medication from Novartis are two such dominant players in the Indonesia Adult Malignant Glioma Therapeutics Market. Locally made generic versions of chemotherapeutic medications, such as those offered by Kalbe Farma, are becoming more and more popular and giving patients more affordable treatment alternatives.

Market Dynamics

Market Growth Drivers

Government Initiatives: BPJS Kesehatan, the Indonesian government's initiative for Universal Health Coverage (JKN), is a major factor in increasing access to cancer treatment and other healthcare services. This program makes treatment more accessible to a larger population by covering necessary chemotherapy medications like bevacizumab and temozolomide. Government programs encouraging the local manufacture of generic medications may also spur market expansion since they reduce treatment costs and increase accessibility for the general public.

Growing Economic Power: The growing middle class in Indonesia has more disposable income, which increases their willingness to spend on medical care, including glioma treatment. This results in a need for both cutting-edge, expensive medicines and reasonably priced generic drugs.

Increasing Local Research & Investment Initiatives: Access to cutting-edge diagnostic and therapeutic technologies is being improved by large investments made throughout Indonesia in cancer centers and specialty hospitals. Additionally, organizations like Cipto Mangunkusumo Hospital and the National Cancer Institute of Indonesia are actively engaged in clinical studies for novel glioma medicines. The goal of these initiatives is to create treatment choices that are accessible and cheap, specifically catered to the requirements of Indonesian citizens.

Market Restraints

Unequal Allocation of Healthcare Resources and Expertise: The majority of modern treatment facilities, such as cancer centers and specialist oncologists, are primarily located in metropolitan regions, leaving rural communities underserved. This regional difference poses serious challenges to prompt diagnosis, the start of treatment, and access to quality care. The lack of qualified healthcare workers makes this access gap even worse.

Regulatory Hurdles and Market Access Issues: Difficult and drawn-out regulatory procedures for bringing new medications to the Indonesian market may cause patients to miss out on cutting-edge treatments. Pharmacies may be deterred from joining the market by onerous regulations and bureaucratic processes, which would reduce the number of available treatments. Counterfeit pharmaceuticals can also jeopardize patient safety and reduce the effectiveness of treatment.

Public Knowledge and Stigma: A lack of knowledge regarding gliomas, their symptoms, and available treatments might cause people to put off getting a diagnosis and be reluctant to seek medical attention. Cancer sufferers are further deterred from coming forward and seeking accessible care by the societal stigma attached to the disease. These problems may serve as market barriers.

Healthcare Policies and Regulatory Landscape

Indonesia's Universal Health Coverage Program (JKN) is a comprehensive endeavour that strives to provide equal access to basic healthcare services. JKN uses the required insurance payments to pay for a wide range of services, including cancer treatment. Notably, Indonesia emphasizes primary care and the integration of traditional medicine while empowering local governments through its decentralized structure. Prioritizing prevention and early diagnosis is key to addressing pervasive issues such as inadequate funding for JKN, unequal access in urban and rural regions, and a scarcity of healthcare workers. The National Agency for Drug and Food Control (BPOM) is the highest authority on drug control. BPOM protects medication costs and safety using a variety of measures, including quality control, manufacturing monitoring, registration, and price controls. Protracted registration procedures, administrative roadblocks, and changing rules frequently test the endurance of pharmaceutical companies.

Competitive Landscape

Key Players

• Roche
• Novartis
• Merck & Co.
• Pfizer
• Bristol-Myers Squibb
• Kalbe Farma
• Stryker
• Elekta
• Siemens